<DOC>
	<DOCNO>NCT00280969</DOCNO>
	<brief_summary>A selection study treatment naive HIV patient compare virologic success rate daily antiretroviral treatment regimen 48th week Epzicom ( lamivudine abacavir ) plus efavirenz Epzicom plus ritonavir boost atazanavir . The superior regimen hire comparative study current first line regimen ( tenofovir plus lamivudine plus efavirenz )</brief_summary>
	<brief_title>Comparing Effectiveness Between Ritonavir Boosted Atazanavir Efavirenz First HIV Treatment</brief_title>
	<detailed_description>A selection study treatment naive HIV patient compare virologic success rate daily antiretroviral treatment regimen 48th week Epzicom ( lamivudine abacavir ) plus efavirenz Epzicom plus ritonavir boost atazanavir . The superior regimen hire comparative study current first line regimen ( tenofovir plus lamivudine plus efavirenz ) The primary endpoint antiretroviral effect 48th week . The secondary endpoint ; 1 . Evaluation immunological effect safety 48 week . 2.Evaluation antiretroviral effect , immunological effect safety 49 96 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>serological diagnosis HIV infection male age 20 year old CD4 enrollment 100 300 body weight 40kg enable obtain write informed consent Patients consider unable complete 48 week study physician . Patients gastrointestinal symptom may interfere absorption antiretrovirals , swallow problem . Patients history hypersensitivity lamivudine . Hepatitis B carrier . Blood test result within 4 week prior randomization ; hemoglobin less 9g/dl , platelet le 50,000/mm3 , neutrophils less 1000/mm3 , serum total bilirubin 2.0mg/dl , GOT/GPT/LDH two time upper normal limit , serum creatinine 1.2mg/dl . Patients radiation chemotherapy within 4 week prior randomization treatment study . Patients immunomodulating agent systemic use corticosteroid interferon within 4 week prior randomization . Inhaled corticosteroid exception . Patients diabetes , congestive heart failure , cardiomyopathy , serious medical condition . Patients AIDS define illness . Patients know resistant strain efavirenz , atazanavir , ritonavir , lamivudine abacavir prior study . Patients acute retroviral syndrome . Patients psychiatric disorder . Patients whose physician consider study enrollment inappropriate .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>treatment</keyword>
	<keyword>efavirenz</keyword>
	<keyword>atazanavir</keyword>
	<keyword>ritonavir</keyword>
</DOC>